CCM
SMMT icon

CTC Capital Management’s Summit Therapeutics SMMT Stock Holding History

CTC Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$17.7K Buy
+10,100
New +$27.5K 0.04% 71

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

CTC Capital Management's SMMT Position: Q1 2023 in Review

CTC Capital Management opened a new position in Summit Therapeutics (SMMT) in Q1 2023: 10,100 shares worth $17.7K. The stake represents 0.04% of the portfolio and ranks #71 among its holdings.

91 funds tracked by Wall St. Rank hold SMMT as of Q1 2023.

  • CTC Capital Management held 10,100 shares of Summit Therapeutics worth $17.7K as of Q1 2023.
  • Summit Therapeutics was a new CTC Capital Management position in Q1 2023.
  • Summit Therapeutics made up 0.04% of CTC Capital Management's portfolio in Q1 2023, its #71 holding.
  • 91 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.